Belite Bio, Inc BLTE
152.17 USD -1.50 (-0.98%)
At closeNov 3, 2026, 4:00 PM EST
152.17 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
152.03 Day range 157.47
102.00 52-week range 200.00
- YTD
- -4.87%
- 1 year
- +35.38%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 227.44 +49.5% upside
Now 152.17
- Target (low)
- 185.00
- Target (mean)
- 227.44
- Target (high)
- 303.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy2
- Buy7
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.76875 | -1.16 – -0.52 | -0.65 | -18.3% | 0 | 0.0% | 8 |
| Next quarter | -0.90375 | -1.43 – -0.51 | -0.70 | -29.1% | 0 | 0.0% | 8 |
| Current year | -2.94 | -3.97 – -1.30 | -2.31 | -27.1% | 0 | 0.0% | 8 |
| Next year | 2.26 | -2.87 – 15.37 | -2.94 | +177.0% | 274.23M | 0.0% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 9, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Sep 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 4, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Aug 14, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 14, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 26, 2026 | Mizuho | Maintained | Outperform | Outperform |
| May 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 22, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 3, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Mar 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jan 28, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 26, 2026 | B of A Securities | Initiated | — | Buy |
| Jan 6, 2026 | Morgan Stanley | Initiated | — | Overweight |
| Dec 2, 2025 | Mizuho | Upgrade | Neutral | Outperform |
| Dec 1, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 20, 2025 | Mizuho | Initiated | — | Neutral |
| Oct 31, 2025 | Benchmark | Maintained | Buy | Buy |
| Sep 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 15, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 26, 2025 | Benchmark | Reiterated | Buy | Buy |
| Mar 18, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Mar 18, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 21, 2025 | Benchmark | Maintained | Buy | Buy |